Thursday, August 18, 2022
HomeHealthExperimental chewing gum may reduce virus spread; Booster shot protection may be...

Experimental chewing gum may reduce virus spread; Booster shot protection may be longer lasting – Reuters

Nurse Gavriil Hadjioannou holds a vial of the Pfizer-BioNTech vaccine against the coronavirus disease (COVID-19) at the health centre of Karyes, the administrative centre of the all-male Orthodox monastic community of Mount Athos, Greece, November 16, 2021. REUTERS/Alexandros Avramidis
Nov 22 (Reuters) – The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that has yet to be certified by peer review.
Experimental chewing gum reduces virus in saliva
An experimental chewing gum containing a protein that "traps" coronavirus particles could limit the amount of virus in saliva and help curb transmission when infected people are talking, breathing or coughing, researchers believe. The gum contains copies of the ACE2 protein found on cell surfaces, which the virus uses as a gateway to break into cells and infect them. In test-tube experiments using saliva and swab samples from infected individuals, virus particles attached themselves to the ACE2 "receptors" in the chewing gum. As a result, the viral load in the samples fell by more than 95%, the research team from the University of Pennsylvania reported in Molecular Therapy. The gum feels and tastes like conventional chewing gum, can be stored for years at normal temperatures, and chewing it does not damage the ACE2 protein molecules, the researchers said. Using gum to reduce viral loads in saliva , they suggest, would add to the benefit of vaccines and would be particularly useful in countries where vaccines are not yet available or affordable.
Protection may last longer after vaccine booster dose
Protection against COVID-19 from an mRNA vaccine – either the Moderna (MRNA.O) or Pfizer (PFE.N)/BioNTech shots – may last longer after the booster dose than after the original two-shot regimen, researchers speculated based on the results of a small new study. They measured vaccine responses before and after the boosters in 33 healthy middle-aged adults who had received their second doses an average of nine months earlier. Before the boosters, their antibody levels had decreased about 10-fold from levels early after their second dose. By 6 to 10 days after the booster, their antibody levels had climbed 25-fold and were five times higher than after two doses of the vaccine, according to a report posted on Sunday on medRxiv ahead of peer review. In the volunteers who had COVID-19 before being vaccinated, antibody levels after the booster were 50-fold higher than after their infections. "Because these antibody levels are so robust, the booster could potentially give us protection for a longer duration than what we saw for two doses of the vaccine," study coauthor Alexis Demonbreun of Northwestern University Feinberg School of Medicine in Chicago, said in a statement.
Blood test detects virus exposure without antibodies
Because not everyone produces measurable amounts of COVID-19 antibodies after infection or vaccination, UK researchers have developed a single blood test that not only detects antibodies but also measures other signs of an immune system response to the virus. Specifically, it measures T cells, powerful immune cells that learn to recognize the virus either after encountering it during infection or through vaccination. As part of the new test, blood samples are exposed to replicas of small pieces of the virus. If the T cells in the blood sample recognize these pieces, they are triggered to produce molecules that can be easily measured, such as the inflammatory protein interferon-gamma. "The test is very sensitive and seems to be accurate," said Martin Scurr of Cardiff University School of Medicine, coauthor of a report published in Immunology. This was true even in patients with cancer, many of whom do not produce antibodies in response to vaccination. "The test is easy to employ and should play a very useful role" in monitoring antibody and T cell responses to the virus, Scurr said. "However, it remains to be determined what level of antibody and T cell response against the virus might protect from future infection and COVID-19."
Click for a Reuters graphic on vaccines in development.
Our Standards: The Thomson Reuters Trust Principles.
Subscribe for our daily curated newsletter to receive the latest exclusive Reuters coverage delivered to your inbox.
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.
Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2021 Reuters. All rights reserved




Please enter your comment!
Please enter your name here

Most Popular

Recent Comments